A Study of Incoxil Food Supplement in Female Patients With Stress Dominant Urinary Incontinence.
Study Details
Study Description
Brief Summary
The purpose of this study is compare the effectiveness of Incoxil food supplement and pelvic floor muscle training with pelvic floor muscle training alone in the treatment of women with stress dominant urinary incontinence.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Pelvic floor muscle training (PFMT) is the first line therapy recommended for the treatment of stress urinary incontinence. The study aims to investigate how poor pelvic floor muscle function can be strengthened by performing pelvic floor exercise and using a special dietary supplement at the same time, and if stress urinary incontinence can be improved more effectively than by performing pelvic floor exercise alone.
The study aims to compare the clinical improvement in the symptoms of stress urinary incontinence in women who do pelvic floor muscle training exercise (PFMT) or who do PFMT exercise and use a dietary supplement. Incoxil dietary supplement contains ingredients that are specifically designed to help strengthen muscles (creatine, l-leucine, zinc, calcium and magnesium).
The randomized controlled clinical trial is proposed involving 34 women diagnosed with stress dominant urinary incontinence and randomized into two groups: 1) treatment with Incoxil dietary supplement and PFMT; 2) treatment with placebo dietary supplement and PFMT. All women will perform PFMT daily and women in group 1 take Incoxil every day, while women in the control group will take daily placebo dietary supplement for 6 weeks.
At baseline assessment, patients shall undergo anamnesis, general gynecological exam, assessments of the pelvic floor based on the modified Oxford scale, the presence of prolapse using the Pelvic Organ Prolapse Quantification (POP-Q) system, pelvic muscle contraction will be measured using a pelvic Perineometer and Vaginal Tactile Imaging will be used for evaluation of vaginal and pelvic floor conditions. We also assess the general health of the vagina with Vaginal Health Index scores. Participants shall complete UDI-6, PGI-S/I and IIQ-7 questionnaires.
After 6 weeks treatment the same assessments will be done to compare treatment and control group results.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Incoxil supplement group Incoxil supplement-group: receive daily oral Incoxil supplementation and perform pelvic floor muscle exercise (PFME) for 6 weeks. |
Dietary Supplement: Incoxil food supplement and pelvic floor muscle exercise
Incoxil supplement group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive Incoxil food supplement and take the supplement once a day.
Incoxil composition: creatine, l-leucine, zinc, calcium and magnesium. Incoxil is specifically designed to contain ingredients that help strengthen muscles during regular resistance training of moderate intensity.
|
| Active Comparator: Control group Control group: receive placebo oral daily supplementation and perform pelvic floor muscle exercise (PFME) for 6 weeks. |
Other: Pelvic floor muscle exercise
Group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive placebo food supplement to take once a day.
|
Outcome Measures
Primary Outcome Measures
- UDI-6 score [6 weeks]
Comparison of Urogenital Distress Inventory-6 (UDI-6) questionnaire final scores before and after treatment in the two arms.
Secondary Outcome Measures
- Incontinence Impact Questionnaire (IIQ-7) score [6 weeks]
Comparison of Incontinence Impact Questionnaire (IIQ-7) questionnaire final scores before and after treatment in the two arms.
- Patient's Global Impression of Severity (PGI-S) [6 weeks]
Comparison of Patient's Global Impression of Severity (PGI-S) questionnaire final scores before and after treatment in the two arms.
- Patient's Global Impression of Improvement (PGI-I) [6 weeks]
Patients will be asked answer the PGI-I questionnaire after the 6 week course of therapy.
- Vaginal Tactile Imager (VTI) score [6 weeks]
VTI is used for evaluation of vaginal and pelvic floor conditions at week 0 and week 6, before and after treatment. VTI allows assessment of tissue elasticity, pelvic floor support and function.
- Vaginal squeeze pressure [6 weeks]
Pelvic muscle contraction will be measured at week 0 and week 6 using a pelvic perineometer to assess any improvement in pelvic muscle strength.
Eligibility Criteria
Criteria
Inclusion Criteria:
- stress UI or stress-dominant mixed UI (stress percent score more than urge percent score)
Exclusion Criteria:
-
pregnancy or less than 12-month postpartum
-
more than three vaginal deliveries or any prior operative delivery
-
self-reported symptoms of pelvic organ prolapse or POP-Q stage >2
-
history of supervised PFMT within 12 months
-
current medications for UI
-
known zinc or copper deficiency or sensitivity
-
connective tissue disease
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dr. Secret Private Clinic | Debrecen | HB | Hungary | 4032 |
Sponsors and Collaborators
- FEMPHARMA Kft.
Investigators
- Principal Investigator: Bence Kozma, MD PhD, Dr. Secret Private Clinic Debrecen Hungary
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2022INCOXIL